Literature DB >> 15123159

Human severe acute respiratory syndrome (SARS) and feline coronaviroses.

Saverio Paltrinieri.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 15123159      PMCID: PMC7129846          DOI: 10.1016/j.jfms.2003.11.001

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


× No keyword cloud information.
A novel coronavirus (CoV) has been isolated from humans with severe acute respiratory syndrome (SARS) (Drosten et al., 2002; Ksiazek et al., 2003). Its pathogenic role, however, is debated, since SARSCoVs have not been identified in all patients with SARS (Ksiazek et al., 2003). The SARSCoV and the feline coronaviruses (FCoV) are phylogenetically quite distant (http://www.cdc.gov/ncidod/sars/pdf/proteinanalysis.pdf): nevertheless SARS and FCoV infections share many common features. Indeed, some differences between the two diseases are detectable, probably due to a different pathogenesis: although it cannot be excluded that the host reactions are responsible for SARS lesions, the SARSCoV is probably directly cytopathic (Ksiazek et al., 2003). In contrast, FIP lesions are due to both type III and type IV hypersensitivity reactions (Paltrinieri et al., 1998): as a consequence, FIP is a systemic disease and usually affects young cats or cats with good body conditions, which have a more responsive immune system, while SARS is confined to the lung and is particularly severe in debilitated patients; during FIP the immune reaction induces typical electrophoretic changes (not reported during SARS) and a lymphoplasmocytic infiltration in the lesions (syncytial cells characterise SARS lesions); finally, no therapies are effective for FIP, while SARS can be treated with antiviral or supportive therapies. The similarities between FIP and SARS further support the hypothesis of the pathogenic role of the SARSCoV. Moreover, FCoV biology has been extensively investigated and further studies on spontaneous cases of FIP might help the scientific community to draw useful information about the SARSCoV. Human CoVs and the feline enteric coronavirus (FECV) are low pathogenic and induce mildinflammations. In contrast, SARS and feline infectious peritonitis (FIP) are due to mutated and highly pathogenic CoVs (Vennema, 1999): the SARSCoV probably arises from animal CoVs (Ksiazek et al., 2003); due to the above mentioned genetic differences between the SARSCoV and the FCoVs it is very unlikely that cats might play a role in the SARS pathogenesis. However, also type II FCoVs probably originated by a recombination between type I FCoVs and canine CoVs (CcoV) (Herrewegh et al., 1998). SARS and FCoVs share a similar epidemiology (both the viruses rapidly spread within susceptible populations and the mortality rate is low) and similar clinico-pathological changes (lymphopenia and increased acute phase proteins are reported in both the diseases) (Drostenet al., 2002; Pedersen, 1995; Sparkes et al., 1994). Gross and microscopic pulmonary lesions are very similar: in particular alveolar damage, necrosis and macrophage infiltration can be detected both in SARS (Ksiazek et al., 2003) and FIP (Fig. 1).
Figure 1

Lung from a cat with feline infectious peritonitis (FIP). A: multifocal to coalescing severe acute fibrinous pleuropneumonia; B: diffuse alveolar damage, with epithelial necrosis and sloughing and accumulation of macrophages and plasma cells. Hematoxylin and eosin, 100×; C: two FCoV-positive cells (macrophages). Immunohistochemistry with anti-FCoV monoclonal antibody, Mayer's hematoxylin counterstain, 100×.

Lung from a cat with feline infectious peritonitis (FIP). A: multifocal to coalescing severe acute fibrinous pleuropneumonia; B: diffuse alveolar damage, with epithelial necrosis and sloughing and accumulation of macrophages and plasma cells. Hematoxylin and eosin, 100×; C: two FCoV-positive cells (macrophages). Immunohistochemistry with anti-FCoV monoclonal antibody, Mayer's hematoxylin counterstain, 100×. Anti-FCoV antibodies identified SARSCoVs in cell cultures, but no CoVs have been immunohistochemically detected within affected lung using different anti-CoV antibodies (Ksiazeket al., 2003). Interestingly, few FCoVs can be detected in large FIP lesions (Kipar et al., 1998; Paltrinieri et al., 1998).
  6 in total

1.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

Authors:  Christian Drosten; Stephan Günther; Wolfgang Preiser; Sylvie van der Werf; Hans-Reinhard Brodt; Stephan Becker; Holger Rabenau; Marcus Panning; Larissa Kolesnikova; Ron A M Fouchier; Annemarie Berger; Ana-Maria Burguière; Jindrich Cinatl; Markus Eickmann; Nicolas Escriou; Klaus Grywna; Stefanie Kramme; Jean-Claude Manuguerra; Stefanie Müller; Volker Rickerts; Martin Stürmer; Simon Vieth; Hans-Dieter Klenk; Albert D M E Osterhaus; Herbert Schmitz; Hans Wilhelm Doerr
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

2.  Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus.

Authors:  A A Herrewegh; I Smeenk; M C Horzinek; P J Rottier; R J de Groot
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  A novel coronavirus associated with severe acute respiratory syndrome.

Authors:  Thomas G Ksiazek; Dean Erdman; Cynthia S Goldsmith; Sherif R Zaki; Teresa Peret; Shannon Emery; Suxiang Tong; Carlo Urbani; James A Comer; Wilina Lim; Pierre E Rollin; Scott F Dowell; Ai-Ee Ling; Charles D Humphrey; Wun-Ju Shieh; Jeannette Guarner; Christopher D Paddock; Paul Rota; Barry Fields; Joseph DeRisi; Jyh-Yuan Yang; Nancy Cox; James M Hughes; James W LeDuc; William J Bellini; Larry J Anderson
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

4.  Genetic drift and genetic shift during feline coronavirus evolution.

Authors:  H Vennema
Journal:  Vet Microbiol       Date:  1999-09-01       Impact factor: 3.293

5.  Some aspects of humoral and cellular immunity in naturally occuring feline infectious peritonitis.

Authors:  S Paltrinieri; M P Cammarata; G Cammarata; S Comazzi
Journal:  Vet Immunol Immunopathol       Date:  1998-10-23       Impact factor: 2.046

6.  Cellular composition, coronavirus antigen expression and production of specific antibodies in lesions in feline infectious peritonitis.

Authors:  A Kipar; S Bellmann; J Kremendahl; K Köhler; M Reinacher
Journal:  Vet Immunol Immunopathol       Date:  1998-10-23       Impact factor: 2.046

  6 in total
  4 in total

1.  Repurposing old drugs as antiviral agents for coronaviruses.

Authors:  Cheng-Wei Yang; Tzu-Ting Peng; Hsing-Yu Hsu; Yue-Zhi Lee; Szu-Huei Wu; Wen-Hsing Lin; Yi-Yu Ke; Tsu-An Hsu; Teng-Kuang Yeh; Wen-Zheng Huang; Jiunn-Horng Lin; Huey-Kang Sytwu; Chiung-Tong Chen; Shiow-Ju Lee
Journal:  Biomed J       Date:  2020-05-23       Impact factor: 4.910

2.  Artificial intelligence approach fighting COVID-19 with repurposing drugs.

Authors:  Yi-Yu Ke; Tzu-Ting Peng; Teng-Kuang Yeh; Wen-Zheng Huang; Shao-En Chang; Szu-Huei Wu; Hui-Chen Hung; Tsu-An Hsu; Shiow-Ju Lee; Jeng-Shin Song; Wen-Hsing Lin; Tung-Jung Chiang; Jiunn-Horng Lin; Huey-Kang Sytwu; Chiung-Tong Chen
Journal:  Biomed J       Date:  2020-05-15       Impact factor: 4.910

3.  Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus.

Authors:  Li-En Hsieh; Chao-Nan Lin; Bi-Ling Su; Tong-Rong Jan; Chi-Min Chen; Ching-Ho Wang; Dah-Sheng Lin; Chung-Tien Lin; Ling-Ling Chueh
Journal:  Antiviral Res       Date:  2010-08-23       Impact factor: 5.970

Review 4.  COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.

Authors:  Wenyi Guan; Wendong Lan; Jing Zhang; Shan Zhao; Junxian Ou; Xiaowei Wu; Yuqian Yan; Jianguo Wu; Qiwei Zhang
Journal:  Virol Sin       Date:  2020-09-30       Impact factor: 4.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.